Background-Prolonged myocardial ischemia results in cardiomyocyte loss despite successful revascularization. We have reported that retrograde application of embryonic endothelial progenitor cells (eEPCs) provides rapid paracrine protection against ischemia-reperfusion injury. Here, we investigated the role of thymosin ␤4 (T␤4) as a mediator of eEPC-mediated cardioprotection. Methods and Results-In vitro, neonatal rat cardiomyocytes were subjected to hypoxia-reoxygenation in the absence or presence of eEPCs with or without T␤4 short hairpin RNA (shRNA) transfection. In vivo, pigs (nϭ9 per group) underwent percutaneous left anterior descending artery occlusion for 60 minutes on day 1. After 55 minutes of ischemia, control eEPCs (5ϫ10 6 cells) or cells transfected with T␤4 shRNA when indicated or 15 mg T␤4 alone were retroinfused into the anterior interventricular vein. Segmental endocardial shortening in the infarct zone at 150-bpm atrial pacing, infarct size (triphenyl tetrazolium chloride viability and methylene blue exclusion), and inflammatory cell influx (myeloperoxidase activity) were determined 24 hours later. Survival of neonatal rat cardiomyocytes increased from 32Ϯ4% to 90Ϯ2% after eEPC application, an effect sensitive to shRNA transfection compared with T␤4 (45Ϯ7%). In vivo, infarct size decreased with eEPC application (38Ϯ4% versus 54Ϯ4% of area at risk; PϽ0.01), an effect abolished by T␤4 shRNA (62Ϯ3%). Segmental subendocardial shortening improved after eEPC treatment (22Ϯ3% versus Ϫ3Ϯ4% of control area) unless T␤4 shRNA was transfected (Ϫ6Ϯ4%). Retroinfusion of T␤4 mimicked eEPC application (infarct size, 37Ϯ3%; segmental endocardial shortening, 34Ϯ7%). Myeloperoxidase activity (3323Ϯ388 U/mg in controls) was decreased by eEPCs (1996Ϯ546 U/mg) or T␤4 alone (1455Ϯ197 U/mg) but not T␤4 shRNA-treated eEPCs (5449Ϯ829 U/mg). Conclusion-Our findings show that short-term cardioprotection derived by regional application of eEPCs can be attributed, at least in part, to T␤4. (Circulation. 2008;117:2232-2240.)
factors for vascular 12, 13 and parenchymal cells 14, 15 has gained recent support. Consistent with this paradigm, embryonic endothelial cells exert postischemic cardioprotection by paracrine factors activating the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway in cardiomyocytes in vitro and in vivo. 16 Screening the transcriptome of the embryonic EPC (eEPC) population by the Affymetrix array technique revealed that among the known PI3K/AKT activating factors, thymosin ␤4 (T␤4), a short peptide of 43 amino acids, is expressed most abundantly. 17 Because T␤4 has recently been reported to exert a profound cardioprotective effect after exogenous application in an acute myocardial infarction model in mice, 18 we hypothesized that this peptide is of relevance for eEPC-derived cardioprotection after ischemia and reperfusion in a preclinical pig model. Therefore, in the present study, we modulated the T␤4 production of eEPCs by specific short hairpin RNA (shRNA) transfection or exogenously applied T␤4 via retroinfusion and investigated the corresponding postischemic myocardial injury.
Methods

Animals
German pigs were purchased from a local farm (Oberschleissheim, Germany). Animal care and all experimental procedures were performed in strict accordance to the German and National Institutes of Health animal legislation guidelines and were approved by the local animal care and use committees.
Reagents
All chemicals were purchased from Sigma (Deisenhofen, Germany). Contrast agent Solutrast 370 was provided by Byk Gulden (Konstanz, Germany). 125 I and 123 I were from Amersham/GE (Braunschweig, Germany).
eEPC Studies
Mouse eEPCs were generated by isolating genetically marked cells from a transgene mouse strain carrying a ␤-galactosidase reporter gene instead of 1 thrombomodulin allele. 19 Cells were selected by reporter gene expression, cultivated on a feeder layer as isolated colonies, and then propagated on gelatin-coated plates. 20 All experiments were performed with cells of an individual colony.
shRNAs were obtained with the pSuperior.retro kit from Oligoengine (Seattle, Wash) according to the manufacturer's instructions. Sequences for scrambled shRNA were 5Ј-TTCTCCGAAC-GTGTCACGT-3Ј and 5Ј-ACGTGACACGTTCGGAGAA-3Ј and for T␤4 were 5Ј-AGAAGCAA-GCTGGCGAATCGTAA-3Ј and 5Ј-TTACGATTCGCC-AGCTTGCTTCT-3Ј. Transfection of eEPCs with shRNA was performed with Lipofectamine (Invitrogen, Karlsruhe, Germany). Verification of shRNA efficacy was achieved by real-time polymerase chain reaction.
RNA Modulation and Detection
Total RNA was extracted from eEPCs, treated with DNaseI (Invitrogen), and converted to cDNA. Real-time polymerase chain reaction was performed with SYBR green dye (iQ SYBR Green Supermix, Bio-Rad, Munich, Germany) and run on the iQ-Cycler (Bio-Rad). Primer pairs for T␤4 were 5Ј-CACGAGCATTGCCTTCTTAT-3Ј and 5Ј-TCTCTGCTAGCCA-GACCATC-3Ј. These were normalized to GAPDH (5Ј-AATTCAACGGCACAGTCAAG-3Ј and 5Ј-ATGGTGGT-GAAGACACCAGT-3Ј). Polymerase chain reaction-amplified products also were separated electrophoretically on 2% agarose gels to confirm that single bands were amplified (data not shown). shRNAs were obtained using the pSuperior.retro kit from Oligoengine according to the manufacturer's instructions. Sequences for scrambled shRNA were 5Ј-TTCTCCGAAC-GTGTCACGT-3Ј and 5Ј-ACGTGACACGTTCGGAGAA-3Ј and for T␤4 were 5Ј-AGAAGCAA-GCTGGCGAATCGTAA-3Ј and 5Ј-TTACGATTCGCC-AGCTTGCTTCT-3Ј.
Cardiomyocyte and Endothelial Cell Culture
Rat neonatal ventricular cardiomyocytes were prepared as previously described. 16 After plating on 6-well plates, hypoxia was induced for 4 hours, followed by reoxygenation for 1 hour. When indicated, eEPCs were placed in a permeable insert (Biocoat, Becton Dickinson, Heidelberg, Germany) in the well before hypoxia. The T␤4 antibody sc-32405 was from Santa Cruz (Heidelberg, Germany). At the end of the experiment, Trypan blue was added for 2 minutes, and 5 microscopic fields were photographed and quantified (Zeiss AxioVision, Göttingen, Germany).
Rat neonatal coronary endothelial cells were obtained by collagenase and trypsin digestion of neonatal rat hearts, seeding for 1 hour on collagen-coated dishes, removal of nonadherent cells, and cultivation in DMEM containing 10% FBS. Neonatal coronary endothelial cells were subjected to hypoxia (18 hours) and reoxygenation (4 hours). Thereafter, cells were fixated with paraformaldehyde (4% in PBS) and analyzed with a commercial terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling staining kit (Roche Diagnostics GmbH, Mannheim, Germany). Application of eEPCs with or without T␤4 shRNA was performed at the onset of hypoxia.
Leukocyte Adhesion
To test the influence of eEPCs or T␤4 on leukocyte adhesion under flow conditions, we seeded primary endothelial cells on microslides (ibidi, Martinsried, Germany). After incubation with eEPCs (50 000 per slide for 4 hours) or T␤4 transfection (24 hours before the experiment with Effectene, Qiagen, Hilden, Germany), microslides were subjected to endothelial activation by interleukin 1␤ (10 ng/mL). Then, we superfused DiI-labeled monocytic cells (THP-1, a gift from P. Nelson, Munich, Germany) at 4 mL/h for 10 minutes. Slides were then rinsed with PBS for 3 minutes. Finally, adherent cells were quantified in 10 high-power fields per slide under fluorescence microscopy.
Pig Ischemia-Reperfusion Model
All pig experiments were conducted at the Institute for Surgical Research at the University of Munich. Pigs (nϭ9 per experimental group) were anesthetized and instrumented as described previously. 16 Briefly, a balloon was placed in the left anterior descending artery (LAD) distal to the bifurcation of the first diagonal branch and inflated with 4 atm (0.41 MPa). Correct localization of the coronary occlusion and patency of the first diagonal branch were ensured by injection of contrast agent. Animals with an obviously abnormal perfusion pattern (area at risk [AAR] Ͻ25% of the left ventricle and/or infarct size Ͻ20% of AAR) were excluded from further analysis (nϭ2). . Effect of T␤4 shRNA on eEPC-mediated cardioprotection in vivo. A, Example of infarct size (percentage of AAR) 24 hours after ischemia and retroinfusion of 5ϫ10 6 eEPCs with T␤4 shRNA. B, Quantification revealed a significant decrease in infarct size after eEPC retroinfusion with or without scrambled (s.c.) shRNA (nϭ9 per group; #PϽ0.01 vs control). C, AAR/left ventricle (LV) did not differ significantly between groups. D, Subendocardial segment shortening (SES) in the apical LAD perfused region (percentage of the nonischemic right circumflex region) at rest and at 120-and 150-bpm atrial pacing (nϭ9 per group; §PϽ0.05 vs control; #PϽ0.05 vs control and eEPC plus T␤4 shRNA). E, Contraction velocity (dP/dtmax) at the given heart rates (Pϭ0.052, 2-way ANOVA).
eEPC Application
As described in detail before, 5ϫ10 6 eEPCs or 15 mg T␤4 (supplied by I. Bock-Marquette, University of Texas, Dallas) was retroinfused into the anterior interventricular vein, draining the LAD-perfused myocardium, after 55 minutes of ischemia for 10 minutes. 16 In all groups, the percutaneous transluminal coronary angioplasty balloon was deflated after 60 minutes of ischemia, and the onset of reperfusion was documented angiographically.
Hemodynamic and Tissue Measurements
After 24 hours of reperfusion, sternotomy was performed and ultrasonic crystals were placed in the noninfarcted and infarcted AAR, as well as in the circumflex perfusion area in a standardized manner. Subendocardial segment shortening was performed under resting heart rate and at 120-and 150-bpm atrial pacing (for 1 minute each). After assessment of infarct size (triphenyl tetrazolium chloride viability and methylene blue exclusion), myeloperoxidase assays were performed as previously described. 16 
Radioactive Labeling of eEPCs
To assess recruitment of native and T␤4 shRNA-treated eEPCs to the ischemic region, tracking via a well-described sodium iodide symporter (NIS) was used. 21, 22 eEPCs were stably transfected with an NIS-containing plasmid (pCDNA3-CMV-NIS, provided by Dr S.M. Jhiang, Ohio State University, Columbus) using Lipofectamine. After selection by G418 for Ϸ2 weeks, surviving cell clones were isolated and subjected to screening for 125 I uptake activity as described earlier. 23 In vivo, 123 I (40 MBq) was systemically applied 24 hours after ischemia. Twenty-five minutes later, hearts were excised. The tissue in the LAD and right circumflex region was separated according to an established segmentation pattern 24 and then analyzed for 123 I accumulation by gamma counter analysis.
High-Performance Liquid Chromatography Analysis
The concentration of T␤4 was determined as described. 25, 26 Briefly, cells were disrupted by adding perchloric acid to the cell suspension to a final concentration of 0.4 mol/L. After incubating for 30 minutes on ice, the mixture was centrifuged for 5 minutes at 20 000g. The supernatant solution was adjusted to pH 4 with NaOH, and an aliquot of the sample was analyzed by reverse-phase high-performance liquid chromatography. 27
Statistical Analysis
The results are given as meanϮSEM. Statistical analysis was done with 1-way ANOVA (SPSS 13.0, SPSS Inc, Chicago, Ill) and, where appropriate, 2-way ANOVA ( Figures 2C and 4C ) or 2-way ANOVA with repeated measures on 1 factor ( Figures 3D, 3E , 6C, and 6D) (SigmaStat, Systat Software Inc, Chicago, Ill). Whenever a significant effect was obtained with ANOVA, we used multiplecomparison tests between groups with the Student-Newman-Keul procedure. Comparisons of 2 groups were performed by 2-sided independent t tests.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
To evaluate the role of T␤4 in vivo, transient downregulation of its RNA was attempted by shRNA transfection. As depicted in Figure 1A and 1B, this approach yielded a downregulation by 77% of the T␤4 mRNA. In accordance, the content of T␤4 per cell decreased from 400 to 150 fg after T␤4 shRNA transfection (data not shown). In vitro, T␤4- specific shRNA transfection or an antibody directed against T␤4 decreased the survival of eEPC-treated cardiomyocytes to the extent of untreated control cells ( Figure 1C and 1D ). Vice versa, U293 cells, which do not contain T␤4, had no beneficial effect on cardiomyocyte survival unless T␤4 was transfected ( Figure 1D ). Endothelial apoptosis after hypoxia and reoxygenation was inhibited by eEPCs unless T␤4 was knocked down ( Figure 1E) . Again, U293 cell cocultivation did not alter endothelial apoptosis unless T␤4 was transfected.
Encouraged by the notion of a T␤4-mediated protection of cardiomyocytes and endothelial cells in vitro, we conducted in vivo experiments of ischemia and reperfusion (see Methods). To exclude an impact of T␤4 shRNA on the adhesion capability of eEPCs in the postischemic myocardium, we used an NIS-expressing eEPC population (Figure 2A and 2B ) that was transfected with T␤4 or control shRNA (see Methods). By virtue of the selectivity of the NIS, 123 I is taken up exclusively by the thyroid gland and NIS-transfected cells. 22 Scintigraphic analysis of the LAD-and right circumflexrelated perfusion area at 24 hours revealed a selective recruitment to the LAD perfused myocardium without a difference caused by T␤4 shRNA transfection ( Figure 2C) .
Applying eEPCs pretreated with T␤4 shRNA, however, was found to reduce the benefit of smaller infarct sizes accomplished by untreated, or control, shRNA-transfected eEPCs ( Figure 3A through 3C) . The impact of T␤4 shRNA treatment on eEPC retroinfusion consistently translated into a decrease in regional myocardial function as assessed by subendocardial segment shortening ( Figure 3D ). Moreover, a strong trend toward a gain in dP/dtmax, a marker of global systolic left ventricular function, 28 which was accomplished by eEPC treatment (Pϭ0.052), was absent in the case of T␤4 shRNA-transfected eEPCs ( Figure 3E ).
One important prognostic parameter of myocardial ischemia-reperfusion injury is postischemic inflammation. In vitro, eEPCs were capable of reducing the amount of adhesive inflammatory cells on an activated endothelial layer under flow conditions ( Figure 4A and 4B) . In vivo, leukocyte influx into the infarcted region, assessed by myeloperoxidase activity, was limited after application of eEPCs as opposed to T␤4 shRNA eEPCs ( Figure 4C) .
To further assess the cardioprotective capability of T␤4, we considered 2 options: application of T␤4 cDNA in a liposomal formulation, which has been successfully applied before, 29, 30 or application of a recombinant protein. Because from a clinical perspective the gene transfer approach implies the disadvantage of treatment 2 days before the ischemic event, we decided to use recombinant T␤4. In vitro, T␤4 protein was able to protect posthypoxic, reoxygenated myocytes and endothelial cells ( Figure 5A and 5B) . Moreover, leukocyte adhesion was reduced by T␤4 in vitro ( Figure 5C ) and in vivo ( Figure 5D ). Finally, T␤4 retroinfusion at the end of the ischemic interval displayed cardioprotection similar to eEPC retroinfusion; infarct size was reduced to 37Ϯ3% ( Figure 6A and 6B) , whereas segmental subendocardial shortening increased (from Ϫ4Ϯ3% to 26Ϯ5% of the nonischemic region at 150 bpm; Figure 6C ). Consistently, global systolic function (dP/dtmax) was found to be increased at rapid pacing ( Figure 6D ).
Taken together, these results show that T␤4, which has cardioprotective properties during hypoxia and reoxygenation in vitro, limits the extent of ischemia-reperfusion injury in vivo if present in large amounts in eEPCs or if applied solely as protein. Consistently, a reduction in T␤4 expression by shRNA diminishes the cardioprotection achieved by an eEPC population, indicating that T␤4 is an essential factor in the acute, eEPC-mediated cardioprotection in vitro and in vivo.
Discussion
In the present study, we investigated the mechanism of cardioprotection observed after transplantation of eEPCs. 17 Given the recent finding that the PI3K/AKT signaling path-way is critically involved in eEPC-mediated limitation of ischemia-reperfusion injury, we screened the eEPC transcriptome for genes encoding secreted proteins capable of activating this pathway. 17 We found that T␤4, one of the most highly expressed AKT-activating factors in our eEPC population, is indeed essential for cardiomyocyte protection in vitro. In particular, T␤4 downregulation by shRNA or an anti-T␤4 antibody blocked the eEPC-mediated increase in cardiomyocyte survival (Figure 1) . Moreover, endothelial apoptosis and adhesion of inflammatory cells were blunted by eEPCs unless T␤4 was knocked down (Figures 1E, 4A , and 4B). In vivo, the decrease in infarct size and postischemic inflammation and the increase in left ventricular function achieved by eEPC retroinfusion were blocked by T␤4 shRNA pretreatment of the eEPCs (Figures 3 and 4C ). Confirming the relevance of eEPC-borne T␤4, exogenous application of the polypeptide in vivo mimicked the cardioprotection achieved by eEPCs ( Figures 5 and 6 ).
Because T␤4 interacts with G-actin and enhances the migratory capacity of differentiated endothelial cells 31 and epicardial vascular progenitor cells in the developing heart, 32 we addressed the possibility of an impaired eEPC recruitment of T␤4 knockdown cells in a subset of experiments. A population of eEPCs expressing NIS, which is otherwise confined to the thyroid gland, 22 was analyzed for recruitment to the heart by measurement of 123 I accumulation. Using this scintigraphic approach, we could rule out an impairment of eEPC recruitment as a potential mechanism for the loss of eEPC-mediated cardioprotection after T␤4 knockdown ( Figure 2) .
The beneficial effect of eEPCs may be achieved by 2 distinct principles: by providing building blocks for novel tissue, ie, vasculature or cardiomyocytes, or by providing paracrine factors as software for cell survival and healing. 33 The eEPC population did not display hallmarks of transdifferentiation, ie, Oct-4 expression or GATA-4 activation, in vitro (data not shown). Moreover, the number of recovered eEPCs declined and was undetectable at day 14 after application in a model of chronic hind-limb ischemia, although a proangiogenic effect persisted at later time points. Therefore, the supply of software by eEPCs aimed at resolving acute and chronic ischemic syndromes appears more likely. This possibility has previously been related to the PI3K/AKT pathway, 16 which is potentially activated by a variety of eEPCborne candidate factors. 17 Among PI3K/AKT activators, the highly expressed T␤4 emerged as a likely candidate because of its functional profile. Other proangiogenic factors such vascular endothelial growth factor-A, platelet-derived growth factor-BB, and insulin-like growth factor-1 are expressed at much lower levels. Moreover, the highly expressed wnt agonists wnt7b and wnt11, activating PI3K/AKT signaling, are not known for cardioprotection (as opposed to the wnt antagonist FrzA 34 ). Other PI3K/AKT activators such as macrophage migration inhibitory factor 35 would counteract the antiinflammatory effect observed in our study (Figure 4) .
On the other hand, T␤4 reduced infarct size in a chronic murine LAD occlusion model, requiring PI3K/AKT signaling. 18 Moreover, T␤4 is capable of mediating angiogenesis in a long-term time course. 32, 36 The short-term protection of reperfused myocardium, which was targeted in the present study, may involve several distinct capabilities of T␤4. In vitro T␤4 incubation blocks cardiomyocyte death after hypoxia and reoxygenation, comparable to the paracrine effect of eEPCs, unless T␤4 is largely diminished by shRNA transfection (Figures 1D and 5A) . Moreover, T␤4 is capable of reducing endothelial apoptosis after the hypoxia-reoxygenation protocol, again similar to the T␤4-containing eEPCs ( Figure 1E, Figure 5B ). In previous studies, we found that protection of endothelial cells, eg, by endothelial nitric oxide synthase or vascular endothelial growth factor cDNA transfection, 29 sufficed to reduce infarct size in our model.
Notably, in all of these studies in the pig ischemiareperfusion model, a reduction in postischemic inflammation was observed. A reduced polymorphonuclear neutrophil influx also has been found after preconditioning and postconditioning 37 and erythropoietin. 38 On the other hand, a direct antiinflammatory effect of T␤4 has been described earlier. 39 In the present study, we confirm that T␤4 decreased the adhesion of inflammatory cells in vitro and in vivo ( Figure  5C and 5D ).
Is T␤4 a major player in adult EPC-mediated cardioprotection? Although adult porcine EPCs also contain about half of the T␤4 content of embryonic eEPCs (data not shown), we refrained from applying adult EPCs at the end of ischemia because of the potentially harmful effects of contaminating inflammatory cells on microvasculatory function and inflammation. Consistent with this notion, a clinical trial using bone marrow-derived EPCs after Ͼ24 hours of reperfusion failed to document a cardioprotective effect, 40 as opposed to the successful Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) study, which applied circulating EPCs after 4 days of reperfusion. 9 However, we caution against extrapolation of our data to other sources of EPCs, which may differ with respect to adhesion, migration, and paracrine effector profiles.
Taken together, these results show that T␤4 reveals a pleiotropic pattern of cardioprotection, including activation of cardiomyocyte survival pathways, inhibition of endothelial apoptosis, and limitation of inflammatory cell recruitment. These mechanisms have been activated by eEPCs containing T␤4 and by application of synthetic T␤4. The therapeutic potential of early T␤4 protein application might be of relevance in the setting of ischemia-reperfusion in patients because no side effects limiting its applicability in this scenario are known yet.
